Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Legend Biotech (LEGN) EBITDA (2019 - 2025)

Legend Biotech filings provide 7 years of EBITDA readings, the most recent being -$19.7 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 75.16% to -$19.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $82.8 million, a 335.54% increase, with the full-year FY2025 number at -$136.5 million, up 55.9% from a year prior.
  • EBITDA hit -$19.7 million in Q4 2025 for Legend Biotech, down from $40.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $45.8 billion in Q4 2023 to a low of -$13.4 billion in Q1 2021.
  • Median EBITDA over the past 5 years was $76.4 million (2021), compared with a mean of $1.7 billion.
  • Biggest five-year swings in EBITDA: tumbled 23850.29% in 2021 and later skyrocketed 41811.57% in 2023.
  • Legend Biotech's EBITDA stood at $89.8 million in 2021, then rose by 21.62% to $109.2 million in 2022, then skyrocketed by 41811.57% to $45.8 billion in 2023, then plummeted by 100.17% to -$79.3 million in 2024, then surged by 75.16% to -$19.7 million in 2025.
  • The last three reported values for EBITDA were -$19.7 million (Q4 2025), $40.6 million (Q3 2025), and $1.2 million (Q2 2025) per Business Quant data.